Calcium pyrophosphate crystal arthritis associated with immune checkpoint inhibitor successfully treated with intra-articular glucocorticoid: A case report
Modern Rheumatology Case Reports · 2025
DOI: 10.1093/mrcr/rxae029 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Kazuya Abe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chondrocalcinosis, Crystal Arthropathies, Glucocorticoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) sometimes induce immune-related adverse events (irAEs), and arthritis is one of the irAE symptoms. Recently, crystal-induced arthritis, such as calcium pyrophosphate (CPP) crystal deposition disease and gout, has been reported to occur after ICI administration. However, the distinction between ICI-associated crystal arthritis and ICI-induced non-crystal arthritis is difficult because their symptoms are similar. Besides, optimal treatment for ICI-associated crystal arthritis has not been established. Here, we report a patient who developed CPP crystal arthritis twice after pembrolizumab (ICI) administration and was successfully treated with intra-articular glucocorticoid injection. He suffered arthritis and acute interstitial nephritis simultaneously after ICI administration. Musculoskeletal ultrasound of his affected joint suggests that his arthritis was crystal-induced arthritis, and arthrocentesis detected CPP crystal in synovial fluid. Thus, we diagnosed his arthritis as ICI-associated crystal arthritis. Therefore, our case encourages the use of musculoskeletal ultrasound in patients with arthritis after treatment with ICI because it may distinguish between ICI-associated crystal arthritis and ICI-induced non-crystal arthritis. Besides, ICI-associated crystal arthritis could be treatable by intra-articular glucocorticoid injection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.
- Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan.
- Research Center for Allergy and Clinical Immunology, Asahi General Hospital, Chiba, Japan.
- Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.
ORCID-Profile: Kazuya Abe
Zitieren
APA
Abe, K., Iwamoto, T., Ikeda, K., Sugiyama, T., Furuta, S., Saito, G., Wakabayashi, H., & Nakajima, H. (2025). Calcium pyrophosphate crystal arthritis associated with immune checkpoint inhibitor successfully treated with intra-articular glucocorticoid: A case report. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxae029
Vancouver
Abe K, Iwamoto T, Ikeda K, Sugiyama T, Furuta S, Saito G, et al. Calcium pyrophosphate crystal arthritis associated with immune checkpoint inhibitor successfully treated with intra-articular glucocorticoid: A case report. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxae029
BibTeX
@article{Abe2025,
author = {Abe, Kazuya and Iwamoto, Taro and Ikeda, Kei and Sugiyama, Takahiro and Furuta, Shunsuke and Saito, Go and Wakabayashi, Hanae and Nakajima, Hiroshi},
title = {Calcium pyrophosphate crystal arthritis associated with immune checkpoint inhibitor successfully treated with intra-articular glucocorticoid: A case report},
journal = {Modern Rheumatology Case Reports},
year = {2025},
doi = {10.1093/mrcr/rxae029}
}
EUVIMED